Welcome
Support Centre
17 May 2008 
ISRCTN Register - International Standard Randomized Controlled Trial Number
Trial registration
Unique identification scheme
International databases
home  |   my details  |   ISRCTN Register  |   mRCT  |   UKCTG  |   links  |   information  |   press
Find trials
ISRCTN Register
tips on searching

Registration
New application
Updating record

Information
introduction
governing board
ISRCTN FAQs
data set
letter of agreement
request information
guidance notes

Submit your study protocol
[ Print-friendly version ]
The efficacy of nasal cavity lavage with a physiological saline solution in prevention of recurrent acute otitis media: a pilot randomised controlled study
ISRCTN ISRCTN50641733
ClinicalTrials.gov identifier
Public title The efficacy of nasal cavity lavage with a physiological saline solution in prevention of recurrent acute otitis media: a pilot randomised controlled study
Scientific title
Acronym N/A
Serial number at source N/A
Study hypothesis We believe that regular nasal irrigation with a physiological saline solution decreases the occurrence of acute otitis media (AOM) and recurrent acute otitis media (rOMA).
Ethics approval Ethics approval received from the Comité d'éthique de la recherche du CHU Saint-Justine on the 28th May 2007 (ref: 2510), last amended 8th January 2008.
Study design Randomised controlled pilot project
Countries of recruitment Canada
Disease/condition/study domain Recurrent acute otitis media
Participants - inclusion criteria 1. Age is between 6 months and 5 years old (exclusively), either sex
2. Recurrent acute otitis media (AOM) (diagnosed by paediatrician or referring general practitioner):
2.1. Four AOM within 6 months
2.2. Six AOM or more within 1 year
Participants - exclusion criteria 1. Parents refuse to participate
2. Known disease or syndrome modifying the normal anatomy or physiology or the upper respiratory tract (Downs, Apert, Crouzon, mucopolysaccharidosis, cranio-cerebral trauma, etc.)
3. Malformations:
3.1. Craniofacial, skull base or nose
3.2. Complete or submucous cleft palate
4. Immunodeficiency:
4.1. Congenital (according to paediatrician or immunologist)
4.2. Acquired (human immunodeficiency virus [HIV], chemotherapy)
5. Ciliary dysfunction (according to paediatrician or pneumologist)
6. Tympanic membrane perforation
7. Cholesteatoma
8. Acute complication of AOM (intra- or extra-cranial)
9. History of ear, nose and throat (ENT) surgery (adenoidectomy, tonsillectomy, myringotomy or other)
10. Intra-nasal or systemic corticosteroid use (pulmonary steroids not excluded)
11. Adenoid or tonsil hypertrophy with suspicion of obstructive apnoea
12. Multiple allergies to antibiotics
13. Insufficient comprehension of written or spoken French by parents
Anticipated start date 24/09/2007
Anticipated end date 01/06/2008
Status of trial Ongoing
Patient information material Not available in web format, please use the contact details below to request a patient information sheet.
Target number of participants 40
Interventions Intervention group:
Nasal irrigation with a physiological saline solution. A 0.9% saline solution is used.
1. If the child is not capable of blowing his nose: 1 cc (full dropper) per nostril, repeated twice, performed four times a day (QID) or six times daily during a respiratory infection
2. If the child is capable of blowing his nose: 5 vaporisations per nostril, blow nose and repeat a second time, perform QID or six times daily during a respiratory infection

Control group:
Patients in the control arm do not perform nasal irrigations.

Treatment lasts 3 months and there are two follow-up visits at 6 weeks intervals.
Primary outcome measure(s) Incidence of recurrent acute otitis media (rAOM) defined as the occurrence of two distinct episodes of acute otitis media during the 3-month study period.
Secondary outcome measure(s) 1. Occurrence of 1 episode of acute otitis media during the 3-month study period
2. Occurrence of adverse events
Sources of funding Sainte-Justine Hospital Research Centre (Centre de recherche du CHU Sainte-Justine) (Canada)
Trial website
Publications
Contact name Dr  Annie  Lapointe
  Address 3175 Cote Sainte-Catherine
  City/town Montreal
  Zip/Postcode H3T 1C5
  Country Canada
  Tel +1 514 345 4857
  Fax +1 514 345 4791
  Email annie.lapointe.hsj@ssss.gouv.qc.ca
Sponsor Sainte-Justine Hospital Research Centre (Centre de recherche du CHU Sainte-Justine) (Canada)
  Address 3175 Côte Sainte-Catherine
  City/town Montreal
  Zip/Postcode H3T 1C5
  Country Canada
  Tel +1 514 345 4691
  Fax +1 514 345 4698
  Email centre@recherche-ste-justine.qc.ca
  Sponsor website: http://www.recherche-sainte-justine.qc.ca/en/
Date applied 20/01/2008
Last edited 16/04/2008
Date ISRCTN assigned 16/04/2008
News
28 Sept 2007: 2007 Update of NHS Trusts Clinical Trials Register now available online
Aug 2007: Searches on ISRCTN register can now be bookmarked
Jul 2007: Patient information material field added to the ISRCTN Register
May 2007: WHO launches the International Clinical Trials Registry Search Portal
3 Apr 2007: Q&As regarding trial registration in the UK
4 Dec 2006: Trials taking place in the UK collated in 'Gateway'

© ISRCTN


BioMed Central